The pharmaceutical company Farmak has supplemented its portfolio with a new brand – hepatic medicine Hep-Art. The drug is available as a lyophilisate solution for injection.
The new product of Farmak – Hep-Art contains an active substance ademetionine.
Ademetionine deficiency plays a key role in the hepatopathy. Reduced ademetionine level deteriorates the liver condition leading to inflammation and further to irreversible structural and degenerative changes in the liver.* Hep-Art eliminates deficiency of the endogenous ademetionine and stimulates its production in the body.
According to the instructions, it is indicated to treat:
intrahepatic cholestasis in adults, including patients with chronic hepatitis of various etiologies and cirrhosis; intrahepatic cholestasis of pregnancy; depressive syndromes.
Olga Vereshchaka, Farmak Product Manager, "Hep-Art helps to restore the liver. Hep-Art acts as an antioxidant; it regenerates hepatic cells, and improves bile production and outflow. The triple action determines 7 effects of Hep-Art: choleretic, cholekinetic, antioxidant, detoxification, regeneration, neuroprotective,** antidepressant. Thus, we are able to treat patients with the intrahepatic cholestasis syndrome, getting improvement in their condition."
The drug is sold by prescription only.
